VBI Vaccines (VBIV) has released an update.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
VBI Vaccines has reported promising interim results from their Phase 2b trial of VBI-1901, an immunotherapeutic cancer vaccine for recurrent glioblastoma, showing a 43% disease control rate compared to 0% in the control group. The vaccine has been granted Fast Track and Orphan Drug Designations by the FDA, with one patient achieving a 67% tumor reduction. Additional data, including survival rates, are expected by the end of 2024, potentially leading to accelerated development and approval discussions.
For further insights into VBIV stock, check out TipRanks’ Stock Analysis page.